BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder), Vimizim , Brineura, Palynziq and Voxzogo. BioMarin has a collaboration agreement with Sanofi's subsidiary Genzyme for Aldurazyme. Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.?The newest drug in BioMarin's portfolio, Voxzogo for treating achondroplasia, the most common form of dwarfism. BioMarin's biologics license application (BLA) for Roctavian/valoctocogene roxaparvovec (valrox), a gene therapy for severe hemophilia A, was given a complete response letter (CRL) by the FDA.
| Revenue (Most Recent Fiscal Year) | $2.85B |
| Net Income (Most Recent Fiscal Year) | $426.86M |
| PE Ratio (Current Year Earnings Estimate) | 16.16 |
| PE Ratio (Trailing 12 Months) | 17.51 |
| PEG Ratio (Long Term Growth Estimate) | 0.77 |
| Price to Sales Ratio (Trailing 12 Months) | 3.65 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.86 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 17.32 |
| Pre-Tax Margin (Trailing 12 Months) | 22.86% |
| Net Margin (Trailing 12 Months) | 17.76% |
| Return on Equity (Trailing 12 Months) | 11.34% |
| Return on Assets (Trailing 12 Months) | 8.95% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.52 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.49 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.10 |
| Inventory Turnover (Trailing 12 Months) | 0.50 |
| Book Value per Share (Most Recent Fiscal Quarter) | $29.69 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.98 |
| Earnings per Share (Most Recent Fiscal Year) | $2.75 |
| Diluted Earnings per Share (Trailing 12 Months) | $2.69 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 191.78M |
| Free Float | 190.15M |
| Market Capitalization | $10.78B |
| Average Volume (Last 20 Days) | 2.23M |
| Beta (Past 60 Months) | 0.19 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.85% |
| Percentage Held By Institutions (Latest 13F Reports) | 98.71% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |